MARKET

PSTI

PSTI

Pluristem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.61
-0.06
-0.69%
After Hours: 8.59 -0.02 -0.23% 16:30 07/13 EDT
OPEN
8.90
PREV CLOSE
8.67
HIGH
9.00
LOW
8.59
VOLUME
267.32K
TURNOVER
--
52 WEEK HIGH
13.29
52 WEEK LOW
2.820
MARKET CAP
214.45M
P/E (TTM)
-1.1364
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average PSTI stock price target is 15.30 with a high estimate of 25.00 and a low estimate of 12.00.

EPS

PSTI News

More
Stocks To Watch: Postmates, Walgreens And Cannabis Plays
Seeking Alpha - Article · 07/04 12:17
Pluristem Is a High Risk, High Reward Play, Says Jefferies Analyst
Just how high can Pluristem Therapeutics (PSTI) climb? The Israeli biotech has outperformed in 2020, with shares up by 94% year-to-date. Driving the micro-cap’s forward charge has been a familiar 2020 narrative. The company’s PLX-PAD cell therapy, which uses a
SmarterAnalyst · 06/24 01:24
Jefferies Initiates Coverage On Pluristem Therapeutics with Buy Rating, Announces Price Target of $12
Jefferies analyst Chris Howerton initiates coverage on Pluristem Therapeutics (NASDAQ:PSTI) with a Buy rating and announces Price Target of $12.
Benzinga · 06/19 11:50
Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in U.S. FDA Phase II COVID-19 ARDS Trial
GlobeNewswire · 06/11 12:00
Pluristem commences mid-stage study of PLX cells in severe COVID-19
Seeking Alpha - Article · 06/11 11:35
Hedge Funds Nibbling On Pluristem Therapeutics Inc. (PSTI)
Insider Monkey · 06/05 21:05
Pluristem Joins Forces with CRISPR-IL National Consortium to Advance Development of Cutting-Edge Genome Editing Solutions for Life Science Products
GlobeNewswire · 06/03 12:00
Pluristem collaborates with CRISPR-IL in genomic research
Seeking Alpha - Article · 06/03 11:30

Industry

Biotechnology & Medical Research
-1.52%
Pharmaceuticals & Medical Research
+0.01%

Hot Stocks

Symbol
Price
%Change

About PSTI

Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
More

Webull offers kinds of Pluristem Therapeutics Inc. stock information, including NASDAQ:PSTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PSTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PSTI stock methods without spending real money on the virtual paper trading platform.